SCHEMBL18893501

SCHEMBL18893501

CC(C)C(NC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(COC(=O)NC(C)(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ MAP1LC3B Q9GZQ8 2/20 0.40
▸ FAP Q12884 5/20 0.40
▸ SIRT2 Q8IXJ6 9/20 0.38
▸ SIRT1 Q96EB6 8/20 0.38
▸ SIRT3 Q9NTG7 4/20 0.38
▸ SIRT5 Q9NXA8 1/20 0.37
▸ FURIN P09958 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18893500 1.00 MAP1LC3B (0.40) MAP1LC3BFAPSIRT2SIRT1SIRT3
SCHEMBL16925417 0.93 MAP1LC3B (0.42) MAP1LC3BFAPSIRT2SIRT1SIRT3
SCHEMBL19982142 0.93 MAP1LC3B (0.41) MAP1LC3BFAPSIRT2SIRT1SIRT3
SCHEMBL16330578 0.90 MAP1LC3B (0.41) MAP1LC3BFAPSIRT2SIRT1SIRT3
SCHEMBL26008568 0.89 MAP1LC3B (0.40) MAP1LC3BFAPSIRT2SIRT1SIRT3
SCHEMBL26009307 0.89 MAP1LC3B (0.40) MAP1LC3BFAPSIRT2SIRT1SIRT3
SCHEMBL10270090 0.88 FURIN (0.39) MAP1LC3BFAPFURIN
SCHEMBL13002105 0.88 FURIN (0.39) MAP1LC3BFAPFURIN
SCHEMBL9943154 0.88 FURIN (0.46) MAP1LC3BFAPFURIN
SCHEMBL14968495 0.88 MAP1LC3B (0.40) MAP1LC3BFAPSIRT2SIRT1SIRT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289785-A1 NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES BANK OF AMERICA, N.A. 2022-09-15 — — US disclosed
US-11117917-B2 Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides SIRNA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-20190153016-A1 NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES BANK OF AMERICA, N.A. 2019-05-23 — — US disclosed
US-10221205-B2 Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides SIRNA THERAPEUTICS, INC. (US) 2019-03-05 — — US disclosed
US-20180079769-A1 NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES BANK OF AMERICA, N.A. 2018-03-22 — — US disclosed
US-9840531-B2 Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides SIRNA THERAPEUTICS, INC. (US) 2017-12-12 — — US disclosed
US-20170306324-A1 NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES BANK OF AMERICA, N.A. 2017-10-26 — — US disclosed
US-20170233731-A1 NOVEL TETRAGALNAC CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES BANK OF AMERICA, N.A. 2017-08-17 — — US disclosed
US-9655976-B2 Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides SIRNA THERAPEUTICS, INC. (US) 2017-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233731-A1 NOVEL TETRAGALNAC CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES CSGALNACT1, GALNT1, FUT6 MAP1LC3B 4268/4885FAP 2211/4885SIRT2 3369/4885
US-20190153016-A1 NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES GALNT3, CSGALNACT1, FUT6 MAP1LC3B 4176/4885FAP 1525/4885SIRT2 3653/4885
US-20220289785-A1 NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES GALNT3, CSGALNACT1, FUT6 MAP1LC3B 4176/4885FAP 1525/4885SIRT2 3653/4885
US-11117917-B2 Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides GALNT3, B3GAT3, CSGALNACT1 MAP1LC3B 4284/4885FAP 1184/4885SIRT2 3885/4885
US-10221205-B2 Tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides GALNT3, B3GAT3, CSGALNACT1 MAP1LC3B 4284/4885FAP 1184/4885SIRT2 3885/4885
US-20180079769-A1 NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES GALNT3, CSGALNACT1, FUT6 MAP1LC3B 4176/4885FAP 1525/4885SIRT2 3653/4885
US-20170306324-A1 NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES GALNT3, CSGALNACT1, FUT6 MAP1LC3B 4176/4885FAP 1525/4885SIRT2 3653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback